ArigatoMoney personal page - To The Moon

ArigatoMoney

ArigatoMoney

No personal profile

58Follow

4Followers

0Topic

0Badge

2021-08-24

$Adamis Pharmaceuticals(ADMP)$A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?

2021-12-20

$Society Pass Inc.(SOPA)$Yay!!

2021-08-05

Nice

Tencent Resumes WeChat Signups

2021-08-06

Now dropping… ??‍♀️

Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week

2021-08-06

Genscript has been one of the stocks i followed

2021-12-22

[Speechless]

@TheSavvyMind:$AMC Entertainment(AMC)$Somebody is afraid of$30 😂

2021-09-10

[Miser]

2021-08-24

Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?

2021-08-24

Advise for US stocks

https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good advise on stocks. He updates on a daily basis.

Advise for US stocks

2022-10-28

$Tiger Brokers(TIGR)$

2021-08-04

[Shy]

China coking coal, coke futures jump as virus fans supply worries

2021-08-04

[Speechless]

Beyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4088854238376920","uuid":"4088854238376920","gmtCreate":1625751176028,"gmtModify":1628068700039,"name":"ArigatoMoney","pinyin":"arigatomoney","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":58,"tweetSize":17,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9986249276,"gmtCreate":1666968758295,"gmtModify":1676537842142,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>","text":"$Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986249276","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000688718,"gmtCreate":1640150341454,"gmtModify":1676533503873,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"[Speechless]&nbsp;","listText":"[Speechless]&nbsp;","text":"[Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000688718","repostId":"9000810420","repostType":1,"repost":{"id":9000810420,"gmtCreate":1640090240359,"gmtModify":1676533500558,"author":{"id":"3571397064539484","authorId":"3571397064539484","name":"TheSavvyMind","avatar":"https://static.itradeup.com/news/90fa6b5b805291648a12010a2cc76211","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3571397064539484","authorIdStr":"3571397064539484"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>Somebody is afraid of$30 😂&nbsp;","listText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>Somebody is afraid of$30 😂&nbsp;","text":"$AMC Entertainment(AMC)$Somebody is afraid of$30 😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000810420","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000182804,"gmtCreate":1640015180256,"gmtModify":1676533498413,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SOPA\">$Society Pass Inc.(SOPA)$</a>Yay!!","listText":"<a href=\"https://ttm.financial/S/SOPA\">$Society Pass Inc.(SOPA)$</a>Yay!!","text":"$Society Pass Inc.(SOPA)$Yay!!","images":[{"img":"https://static.itradeup.com/news/269eeb74dcd484cd73b0fbbabfad1f66","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000182804","isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":883250736,"gmtCreate":1631246873825,"gmtModify":1676530508204,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[{"img":"https://static.tigerbbs.com/c1d81f73c1a2f51e8378d1c31e8b34d7","width":"1125","height":"2879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883250736","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":834249758,"gmtCreate":1629809877074,"gmtModify":1676530137998,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?&nbsp;","listText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?&nbsp;","text":"$Adamis Pharmaceuticals(ADMP)$A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?","images":[{"img":"https://static.tigerbbs.com/4cd5c494cf7ac18ba3ef466c1aa16f4c","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/834249758","isVote":1,"tweetType":1,"viewCount":1134,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3579824629573394","authorId":"3579824629573394","name":"股神lareina","avatar":"https://static.tigerbbs.com/7875819e7f109b6f0da66703f9a72051","crmLevel":2,"crmLevelSwitch":0,"idStr":"3579824629573394","authorIdStr":"3579824629573394"},"content":"only keep one day？","text":"only keep one day？","html":"only keep one day？"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":834249979,"gmtCreate":1629809771891,"gmtModify":1676530137982,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","listText":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","text":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","images":[{"img":"https://static.tigerbbs.com/36a32ed0bf7e7846cb83c9e2af5365a5","width":"1125","height":"3069"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834249979","isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":834265467,"gmtCreate":1629807884559,"gmtModify":1676530137331,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"title":"Advise for US stocks","htmlText":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good&nbsp;advise on stocks. He updates on a daily basis.&nbsp;","listText":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good&nbsp;advise on stocks. He updates on a daily basis.&nbsp;","text":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good advise on stocks. He updates on a daily basis.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834265467","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893294936,"gmtCreate":1628262955825,"gmtModify":1703504276004,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"Now dropping… ??‍♀️","listText":"Now dropping… ??‍♀️","text":"Now dropping… ??‍♀️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893294936","repostId":"2157646054","repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893292749,"gmtCreate":1628262874581,"gmtModify":1703504273982,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"Genscript has been one of the stocks i followed","listText":"Genscript has been one of the stocks i followed","text":"Genscript has been one of the stocks i followed","images":[{"img":"https://static.tigerbbs.com/5caf44d544e7d9e462bc497eb83f1f49","width":"1125","height":"2018"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893292749","isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":899081901,"gmtCreate":1628142445703,"gmtModify":1703502016749,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899081901","repostId":"1135557452","repostType":4,"repost":{"id":"1135557452","kind":"news","pubTimestamp":1628142291,"share":"https://ttm.financial/m/news/1135557452?lang=&edition=fundamental","pubTime":"2021-08-05 13:44","market":"us","language":"en","title":"Tencent Resumes WeChat Signups","url":"https://stock-news.laohu8.com/highlight/detail?id=1135557452","media":"Bloomberg","summary":"Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspendi","content":"<p>Tencent Holdings Ltd.&nbsp;has resumed signing up users for its WeChat messaging app, days after&nbsp;suspending&nbsp;registrations for unspecified technical upgrades.</p>\n<p>WeChat, which already has more than 1 billion users, halted signups last week to undergo a “security technical upgrade” to comply with regulations. The company said at the time it expected to resume new individual user registrations around early August. A company representative confirmed user reports on social media Thursday about the resumption.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent Resumes WeChat Signups</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent Resumes WeChat Signups\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 13:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspending registrations for unspecified technical upgrades.\nWeChat, which already has more than 1 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","TCEHY":"腾讯控股ADR"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135557452","content_text":"Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspending registrations for unspecified technical upgrades.\nWeChat, which already has more than 1 billion users, halted signups last week to undergo a “security technical upgrade” to comply with regulations. The company said at the time it expected to resume new individual user registrations around early August. A company representative confirmed user reports on social media Thursday about the resumption.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890062451,"gmtCreate":1628068169773,"gmtModify":1703500600892,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"[Shy]&nbsp;","listText":"[Shy]&nbsp;","text":"[Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890062451","repostId":"2156729181","repostType":4,"repost":{"id":"2156729181","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628063023,"share":"https://ttm.financial/m/news/2156729181?lang=&edition=fundamental","pubTime":"2021-08-04 15:43","market":"sh","language":"en","title":"China coking coal, coke futures jump as virus fans supply worries","url":"https://stock-news.laohu8.com/highlight/detail?id=2156729181","media":"Reuters","summary":"(Updates with closing prices)\nBEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended ","content":"<p>(Updates with closing prices)</p>\n<p>BEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.</p>\n<p>China on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.</p>\n<p>\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.</p>\n<p>The recent outbreak also delayed efficiency of motor transport for coking coal, it added.</p>\n<p>The most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.</p>\n<p>Coke futures jumped 3.4% to 2,953 yuan a tonne.</p>\n<p>Prices for benchmark iron ore futures on the Dalian bourse&nbsp;also gained, edging up 0.5% to 1,067 yuan per tonne.</p>\n<p>Spot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.</p>\n<p>FUNDAMENTALS</p>\n<ul>\n <li>Construction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.</li>\n <li>Hot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.</li>\n <li>Shanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.</li>\n <li>Zimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.</li>\n</ul>\n<p>($1 = 6.4608 Chinese yuan)</p>\n<p>(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China coking coal, coke futures jump as virus fans supply worries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina coking coal, coke futures jump as virus fans supply worries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-04 15:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Updates with closing prices)</p>\n<p>BEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.</p>\n<p>China on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.</p>\n<p>\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.</p>\n<p>The recent outbreak also delayed efficiency of motor transport for coking coal, it added.</p>\n<p>The most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.</p>\n<p>Coke futures jumped 3.4% to 2,953 yuan a tonne.</p>\n<p>Prices for benchmark iron ore futures on the Dalian bourse&nbsp;also gained, edging up 0.5% to 1,067 yuan per tonne.</p>\n<p>Spot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.</p>\n<p>FUNDAMENTALS</p>\n<ul>\n <li>Construction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.</li>\n <li>Hot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.</li>\n <li>Shanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.</li>\n <li>Zimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.</li>\n</ul>\n<p>($1 = 6.4608 Chinese yuan)</p>\n<p>(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156729181","content_text":"(Updates with closing prices)\nBEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.\nChina on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.\n\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.\nThe recent outbreak also delayed efficiency of motor transport for coking coal, it added.\nThe most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.\nCoke futures jumped 3.4% to 2,953 yuan a tonne.\nPrices for benchmark iron ore futures on the Dalian bourse also gained, edging up 0.5% to 1,067 yuan per tonne.\nSpot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.\nFUNDAMENTALS\n\nConstruction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.\nHot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.\nShanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.\nZimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.\n\n($1 = 6.4608 Chinese yuan)\n(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)","news_type":1},"isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890062013,"gmtCreate":1628068125532,"gmtModify":1703500600395,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"4088854238376920","authorIdStr":"4088854238376920"},"themes":[],"htmlText":"[Speechless]&nbsp;","listText":"[Speechless]&nbsp;","text":"[Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890062013","repostId":"1174986187","repostType":4,"repost":{"id":"1174986187","kind":"news","pubTimestamp":1628062628,"share":"https://ttm.financial/m/news/1174986187?lang=&edition=fundamental","pubTime":"2021-08-04 15:37","market":"us","language":"en","title":"Beyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens","url":"https://stock-news.laohu8.com/highlight/detail?id=1174986187","media":"investing.com","summary":"Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS","content":"<ul>\n <li>Reports Q2 results on Thursday, Aug. 5, after the market close</li>\n <li>Revenue Expectation: $143 billion</li>\n <li>EPS Expectation: loss of $0.23</li>\n</ul>\n<p>Shares of <a href=\"https://laohu8.com/S/BYND\">Beyond Meat, Inc.</a> have remained under pressure throughout the pandemic as the veggie burger-maker struggled to increase its sales when restaurants, stadiums and campuses were closed.</p>\n<p><img src=\"https://static.tigerbbs.com/cb1491a08c273cf4bbed2a97d7f1c340\" tg-width=\"782\" tg-height=\"664\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">BYND Daily</p>\n<p>As the economy reopens and some of these avenues start again, investors are not convinced that sales will come back quickly. BYND shares have fallen 19% during the past month, illustrating investors' nervousness about owning this high-growth stock.</p>\n<p>When the Los Angeles-based company releases its second-quarter earnings tomorrow, one of the most important numbers to analyze is how quickly sales from restaurant and food-service sectors are rebounding.</p>\n<p>Unlike other packaged-food companies, Beyond Meat relies heavily on these segments for growth. The emergence of the Delta variant of COVID-19, which forced many countries to re-impose lockdowns and prompted US health authorities to reinstate mask mandates at indoor settings, is making the revenue outlook more uncertain for BYND.</p>\n<p>Despite the pandemic setback, we continue to believe Beyond Meat is a great food stock to own as consumers become more health conscious. Its recent weakness is a bump in the company’s long-term growth potential. BYND’s latest partnerships and expansion plans validate this bullish case.</p>\n<h2><b>A Clear Lead</b></h2>\n<p>A few years ago the big question was whether fake meat would take off. Now that it’s moving into the mainstream, the global market is projected to reach $450 billion by 2040,&nbsp;accordingto global consulting firm Kearney.</p>\n<p>And when it comes to competition, Beyond Meat is much further along than its closest rival, Impossible Foods. It had more US retailers—28,000 compared with Impossible’s 20,000. Its products were being offered in more restaurants (42,000 in the US vs. 30,000+), and more international markets (more than 80 vs. 5), according to a&nbsp;Bloomberg analysisin April.</p>\n<p>Beyond Meat this year announced several expansion plans that should ease investor anxiety, including a new burger, European retail expansion, and the opening of its production plant in China—its first outside the US—to produce and distribute its plant-based products, including Beyond Pork, created specifically for the Chinese market.</p>\n<p>In January, Beyond Meat finalized its agreements with <a href=\"https://laohu8.com/S/MCD\">McDonald's</a> and <a href=\"https://laohu8.com/S/YUM\">Yum</a>—two of the largest fast-food companies in the world. The three-year deal with McDonald’s makes Beyond Meat the chain’s “preferred supplier” for the McPlant patty. Beyond Meat and McDonald’s will also explore developing other plant-based menu items, including alternative chicken, pork and eggs.</p>\n<h3><b>Bottom Line</b></h3>\n<p>Beyond Meat sales will rebound quickly once the global economy overcomes the pandemic and people resume their routine activities. The company’s leading position in the plant-based food market makes it an ideal candidate to buy on weakness.</p>","source":"lsy1594375853987","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 15:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860><strong>investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS Expectation: loss of $0.23\n\nShares of Beyond Meat, Inc. have remained under pressure throughout the...</p>\n\n<a href=\"https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174986187","content_text":"Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS Expectation: loss of $0.23\n\nShares of Beyond Meat, Inc. have remained under pressure throughout the pandemic as the veggie burger-maker struggled to increase its sales when restaurants, stadiums and campuses were closed.\nBYND Daily\nAs the economy reopens and some of these avenues start again, investors are not convinced that sales will come back quickly. BYND shares have fallen 19% during the past month, illustrating investors' nervousness about owning this high-growth stock.\nWhen the Los Angeles-based company releases its second-quarter earnings tomorrow, one of the most important numbers to analyze is how quickly sales from restaurant and food-service sectors are rebounding.\nUnlike other packaged-food companies, Beyond Meat relies heavily on these segments for growth. The emergence of the Delta variant of COVID-19, which forced many countries to re-impose lockdowns and prompted US health authorities to reinstate mask mandates at indoor settings, is making the revenue outlook more uncertain for BYND.\nDespite the pandemic setback, we continue to believe Beyond Meat is a great food stock to own as consumers become more health conscious. Its recent weakness is a bump in the company’s long-term growth potential. BYND’s latest partnerships and expansion plans validate this bullish case.\nA Clear Lead\nA few years ago the big question was whether fake meat would take off. Now that it’s moving into the mainstream, the global market is projected to reach $450 billion by 2040, accordingto global consulting firm Kearney.\nAnd when it comes to competition, Beyond Meat is much further along than its closest rival, Impossible Foods. It had more US retailers—28,000 compared with Impossible’s 20,000. Its products were being offered in more restaurants (42,000 in the US vs. 30,000+), and more international markets (more than 80 vs. 5), according to a Bloomberg analysisin April.\nBeyond Meat this year announced several expansion plans that should ease investor anxiety, including a new burger, European retail expansion, and the opening of its production plant in China—its first outside the US—to produce and distribute its plant-based products, including Beyond Pork, created specifically for the Chinese market.\nIn January, Beyond Meat finalized its agreements with McDonald's and Yum—two of the largest fast-food companies in the world. The three-year deal with McDonald’s makes Beyond Meat the chain’s “preferred supplier” for the McPlant patty. Beyond Meat and McDonald’s will also explore developing other plant-based menu items, including alternative chicken, pork and eggs.\nBottom Line\nBeyond Meat sales will rebound quickly once the global economy overcomes the pandemic and people resume their routine activities. The company’s leading position in the plant-based food market makes it an ideal candidate to buy on weakness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":834249758,"gmtCreate":1629809877074,"gmtModify":1676530137998,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?&nbsp;","listText":"<a href=\"https://laohu8.com/S/ADMP\">$Adamis Pharmaceuticals(ADMP)$</a>A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?&nbsp;","text":"$Adamis Pharmaceuticals(ADMP)$A friend recommended saying this may be good to buy now, and if FDA approves this home medication, it might increase. Bought it last friday. Any thoughts?","images":[{"img":"https://static.tigerbbs.com/4cd5c494cf7ac18ba3ef466c1aa16f4c","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/834249758","isVote":1,"tweetType":1,"viewCount":1134,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3579824629573394","authorId":"3579824629573394","name":"股神lareina","avatar":"https://static.tigerbbs.com/7875819e7f109b6f0da66703f9a72051","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3579824629573394","idStr":"3579824629573394"},"content":"only keep one day？","text":"only keep one day？","html":"only keep one day？"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9000182804,"gmtCreate":1640015180256,"gmtModify":1676533498413,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SOPA\">$Society Pass Inc.(SOPA)$</a>Yay!!","listText":"<a href=\"https://ttm.financial/S/SOPA\">$Society Pass Inc.(SOPA)$</a>Yay!!","text":"$Society Pass Inc.(SOPA)$Yay!!","images":[{"img":"https://static.itradeup.com/news/269eeb74dcd484cd73b0fbbabfad1f66","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000182804","isVote":1,"tweetType":1,"viewCount":792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":899081901,"gmtCreate":1628142445703,"gmtModify":1703502016749,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899081901","repostId":"1135557452","repostType":4,"repost":{"id":"1135557452","kind":"news","pubTimestamp":1628142291,"share":"https://ttm.financial/m/news/1135557452?lang=&edition=fundamental","pubTime":"2021-08-05 13:44","market":"us","language":"en","title":"Tencent Resumes WeChat Signups","url":"https://stock-news.laohu8.com/highlight/detail?id=1135557452","media":"Bloomberg","summary":"Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspendi","content":"<p>Tencent Holdings Ltd.&nbsp;has resumed signing up users for its WeChat messaging app, days after&nbsp;suspending&nbsp;registrations for unspecified technical upgrades.</p>\n<p>WeChat, which already has more than 1 billion users, halted signups last week to undergo a “security technical upgrade” to comply with regulations. The company said at the time it expected to resume new individual user registrations around early August. A company representative confirmed user reports on social media Thursday about the resumption.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tencent Resumes WeChat Signups</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTencent Resumes WeChat Signups\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-05 13:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspending registrations for unspecified technical upgrades.\nWeChat, which already has more than 1 billion ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00700":"腾讯控股","TCEHY":"腾讯控股ADR"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-05/tencent-resumes-new-wechat-user-signups-after-upgrades?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135557452","content_text":"Tencent Holdings Ltd. has resumed signing up users for its WeChat messaging app, days after suspending registrations for unspecified technical upgrades.\nWeChat, which already has more than 1 billion users, halted signups last week to undergo a “security technical upgrade” to comply with regulations. The company said at the time it expected to resume new individual user registrations around early August. A company representative confirmed user reports on social media Thursday about the resumption.","news_type":1},"isVote":1,"tweetType":1,"viewCount":214,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893294936,"gmtCreate":1628262955825,"gmtModify":1703504276004,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"Now dropping… ??‍♀️","listText":"Now dropping… ??‍♀️","text":"Now dropping… ??‍♀️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893294936","repostId":"2157646054","repostType":4,"repost":{"id":"2157646054","kind":"highlight","pubTimestamp":1628255580,"share":"https://ttm.financial/m/news/2157646054?lang=&edition=fundamental","pubTime":"2021-08-06 21:13","market":"us","language":"en","title":"Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2157646054","media":"Motley Fool","summary":"Each vaccine stock had its own separate catalyst.","content":"<h3>What happened</h3>\n<p>Shares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. <b>Novavax</b> (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. <b>BioNTech</b>'s (NASDAQ:BNTX) shares vaulted 23.3% higher. <b>Moderna</b> (NASDAQ:MRNA) stock jumped 17.7%. Shares of <b>Dynavax Technologies</b> (NASDAQ:DVAX) rose 10.6%.</p>\n<p>Was there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.</p>\n<p><img src=\"https://static.tigerbbs.com/bcfbb91c5df631ab6670c1e77b9a0df3\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Novavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.</p>\n<p>However, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.</p>\n<p>BioNTech and its partner <b>Pfizer</b>&nbsp;benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. <i>The New York Times</i> stated that the expected FDA approval could spur more vaccine mandates by employers.</p>\n<p>Moderna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.</p>\n<p>Dynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.</p>\n<h3>So what</h3>\n<p>Novavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.</p>\n<p>Of the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.</p>\n<p>Moderna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.</p>\n<p>The report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.</p>\n<h3>Now what</h3>\n<p>All four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.</p>\n<p>Both BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy COVID Vaccine Stocks Moderna, BioNTech, Novavax, and Dynavax Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVAX":"德纳维制药","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/08/06/why-covid-vaccine-stocks-moderna-biontech-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2157646054","content_text":"What happened\nShares of several COVID-19 vaccine makers soared this week as of the market close on Thursday. Novavax (NASDAQ:NVAX) was the biggest winner, with its stock skyrocketing 31.7%. BioNTech's (NASDAQ:BNTX) shares vaulted 23.3% higher. Moderna (NASDAQ:MRNA) stock jumped 17.7%. Shares of Dynavax Technologies (NASDAQ:DVAX) rose 10.6%.\nWas there a common denominator for all of these vaccine stocks? Increasing fears about the delta variant likely played a role to some extent. However, each company also had good news of its own.\n\nImage source: Getty Images.\nNovavax announced on Wednesday that the European Commission agreed to purchase up to 200 million doses of its COVID-19 vaccine NVX-CoV2373. The deal includes an initial order of up to 100 million doses with an option to buy an additional 100 million doses through 2023.\nHowever, Novavax provided its second-quarter update following the market close on Thursday. The company now expects to file for Emergency Use Authorization (EUA) in the U.S. in the fourth quarter of 2021 instead of in the third quarter. Its shares gave up some of the week's gains in after-hours trading.\nBioNTech and its partner Pfizer benefited from a report that the U.S. Food and Drug Administration (FDA) will likely approve their COVID-19 vaccine by early September. The New York Times stated that the expected FDA approval could spur more vaccine mandates by employers.\nModerna announced on Tuesday that it had received FDA Fast Track Designation for its respiratory syncytial virus (RSV) vaccine candidate mRNA-1345. The company also reported strong second-quarter results on Thursday and projected vaccine sales of $20 billion for the full year.\nDynavax reported positive Q2 results on Wednesday. The company's revenue of $52.8 million blew past the consensus estimate of $41.6 million.\nSo what\nNovavax had the biggest news of these vaccine makers. The company's European deal could generate a hefty amount of additional revenue over the next couple of years.\nOf the two companies reporting quarterly results, Dynavax delivered the greater upside surprise. Its Heplisav-B hepatitis B vaccine raked in $13.7 million in sales, the highest quarterly figure so far.\nModerna also beat expectations with Q2 revenue of $4.4 billion. Arguably the most important update from the company, though, was that it has already secured supply deals for 2022 totaling $12 billion plus options for another $8 billion.\nThe report about a potential quick FDA approval for the Pfizer-BioNTech vaccine lit a fire beneath BioNTech stock. However, this really wasn't surprising.\nNow what\nAll four companies could have more good news on the way. Novavax is working to file for Emergency Use Authorization for its COVID-19 vaccine candidate by the end of the third quarter in the U.K. and, as previously mentioned, in Q4 in the U.S. Dynavax expects key data readouts this year from several partners who are using its CpG 1018 adjuvant with their experimental COVID-19 vaccines.\nBoth BioNTech and Moderna hope to win full FDA approval for their respective COVID-19 vaccines. The companies are also angling to line up more supply deals for 2022 and beyond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893292749,"gmtCreate":1628262874581,"gmtModify":1703504273982,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"Genscript has been one of the stocks i followed","listText":"Genscript has been one of the stocks i followed","text":"Genscript has been one of the stocks i followed","images":[{"img":"https://static.tigerbbs.com/5caf44d544e7d9e462bc497eb83f1f49","width":"1125","height":"2018"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893292749","isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9000688718,"gmtCreate":1640150341454,"gmtModify":1676533503873,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"[Speechless]&nbsp;","listText":"[Speechless]&nbsp;","text":"[Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000688718","repostId":"9000810420","repostType":1,"repost":{"id":9000810420,"gmtCreate":1640090240359,"gmtModify":1676533500558,"author":{"id":"3571397064539484","authorId":"3571397064539484","name":"TheSavvyMind","avatar":"https://static.itradeup.com/news/90fa6b5b805291648a12010a2cc76211","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3571397064539484","idStr":"3571397064539484"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>Somebody is afraid of$30 😂&nbsp;","listText":"<a href=\"https://ttm.financial/S/AMC\">$AMC Entertainment(AMC)$</a>Somebody is afraid of$30 😂&nbsp;","text":"$AMC Entertainment(AMC)$Somebody is afraid of$30 😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000810420","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":883250736,"gmtCreate":1631246873825,"gmtModify":1676530508204,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[{"img":"https://static.tigerbbs.com/c1d81f73c1a2f51e8378d1c31e8b34d7","width":"1125","height":"2879"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883250736","isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":834249979,"gmtCreate":1629809771891,"gmtModify":1676530137982,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","listText":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","text":"Tempol a home covid medication that is on clinical trial, yet to be approved for use. Any thoughts?","images":[{"img":"https://static.tigerbbs.com/36a32ed0bf7e7846cb83c9e2af5365a5","width":"1125","height":"3069"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834249979","isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":834265467,"gmtCreate":1629807884559,"gmtModify":1676530137331,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"title":"Advise for US stocks","htmlText":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good&nbsp;advise on stocks. He updates on a daily basis.&nbsp;","listText":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good&nbsp;advise on stocks. He updates on a daily basis.&nbsp;","text":"https://youtube.com/channel/UC6hhtmnety48C4IbUo2GKWAThis guy is very good and give very good advise on stocks. He updates on a daily basis.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834265467","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9986249276,"gmtCreate":1666968758295,"gmtModify":1676537842142,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>","text":"$Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986249276","isVote":1,"tweetType":1,"viewCount":178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890062451,"gmtCreate":1628068169773,"gmtModify":1703500600892,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"[Shy]&nbsp;","listText":"[Shy]&nbsp;","text":"[Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890062451","repostId":"2156729181","repostType":4,"repost":{"id":"2156729181","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628063023,"share":"https://ttm.financial/m/news/2156729181?lang=&edition=fundamental","pubTime":"2021-08-04 15:43","market":"sh","language":"en","title":"China coking coal, coke futures jump as virus fans supply worries","url":"https://stock-news.laohu8.com/highlight/detail?id=2156729181","media":"Reuters","summary":"(Updates with closing prices)\nBEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended ","content":"<p>(Updates with closing prices)</p>\n<p>BEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.</p>\n<p>China on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.</p>\n<p>\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.</p>\n<p>The recent outbreak also delayed efficiency of motor transport for coking coal, it added.</p>\n<p>The most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.</p>\n<p>Coke futures jumped 3.4% to 2,953 yuan a tonne.</p>\n<p>Prices for benchmark iron ore futures on the Dalian bourse&nbsp;also gained, edging up 0.5% to 1,067 yuan per tonne.</p>\n<p>Spot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.</p>\n<p>FUNDAMENTALS</p>\n<ul>\n <li>Construction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.</li>\n <li>Hot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.</li>\n <li>Shanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.</li>\n <li>Zimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.</li>\n</ul>\n<p>($1 = 6.4608 Chinese yuan)</p>\n<p>(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China coking coal, coke futures jump as virus fans supply worries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina coking coal, coke futures jump as virus fans supply worries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-04 15:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Updates with closing prices)</p>\n<p>BEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.</p>\n<p>China on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.</p>\n<p>\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.</p>\n<p>The recent outbreak also delayed efficiency of motor transport for coking coal, it added.</p>\n<p>The most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.</p>\n<p>Coke futures jumped 3.4% to 2,953 yuan a tonne.</p>\n<p>Prices for benchmark iron ore futures on the Dalian bourse&nbsp;also gained, edging up 0.5% to 1,067 yuan per tonne.</p>\n<p>Spot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.</p>\n<p>FUNDAMENTALS</p>\n<ul>\n <li>Construction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.</li>\n <li>Hot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.</li>\n <li>Shanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.</li>\n <li>Zimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.</li>\n</ul>\n<p>($1 = 6.4608 Chinese yuan)</p>\n<p>(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156729181","content_text":"(Updates with closing prices)\nBEIJING, Aug 4 (Reuters) - Chinese coking coal and coke futures ended higher on Wednesday, as a recent coronavirus outbreak in the country sparked supply concerns for the steelmaking ingredients.\nChina on Wednesday reported the most new locally transmitted COVID-19 cases since January as some cities stepped up restrictions, cut flights and increased testing to get to grips with an outbreak driven mainly by the Delta variant.\n\"The coronavirus situation has been developing, which affected the turnover rate of coke and arrivals at mills,\" GF Futures wrote in a note.\nThe recent outbreak also delayed efficiency of motor transport for coking coal, it added.\nThe most traded coking coal futures on the Dalian Commodity Exchange , for September delivery, rose 2.3% to 2,314 yuan ($358.16) per tonne at close.\nCoke futures jumped 3.4% to 2,953 yuan a tonne.\nPrices for benchmark iron ore futures on the Dalian bourse also gained, edging up 0.5% to 1,067 yuan per tonne.\nSpot prices of iron ore with 62% iron content for delivery to China, compiled by SteelHome consultancy, was unchanged at $185.5 per tonne on Tuesday.\nFUNDAMENTALS\n\nConstruction steel rebar on the Shanghai Futures Exchange, for October delivery, recovered in morning trade, up 2.5% to 5,454 yuan a tonne.\nHot rolled coils , mostly used in the manufacturing sector, rose 2.7% to 5,853 yuan per tonne.\nShanghai stainless steel futures fell 1.6% to 18,900 yuan a tonne.\nZimbabwe has banned the export of raw chrome with immediate effect in a bid to support the domestic ferrochrome industry, minister of information Monica Mutsvangwa said on Tuesday.\n\n($1 = 6.4608 Chinese yuan)\n(Reporting by Min Zhang and Shivani Singh; Editing by Rashmi Aich and Ramakrishnan M.)","news_type":1},"isVote":1,"tweetType":1,"viewCount":134,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890062013,"gmtCreate":1628068125532,"gmtModify":1703500600395,"author":{"id":"4088854238376920","authorId":"4088854238376920","name":"ArigatoMoney","avatar":"https://static.tigerbbs.com/7fdd63d4d735e78c6522c3b0ca49b71d","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4088854238376920","idStr":"4088854238376920"},"themes":[],"htmlText":"[Speechless]&nbsp;","listText":"[Speechless]&nbsp;","text":"[Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890062013","repostId":"1174986187","repostType":4,"repost":{"id":"1174986187","kind":"news","pubTimestamp":1628062628,"share":"https://ttm.financial/m/news/1174986187?lang=&edition=fundamental","pubTime":"2021-08-04 15:37","market":"us","language":"en","title":"Beyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens","url":"https://stock-news.laohu8.com/highlight/detail?id=1174986187","media":"investing.com","summary":"Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS","content":"<ul>\n <li>Reports Q2 results on Thursday, Aug. 5, after the market close</li>\n <li>Revenue Expectation: $143 billion</li>\n <li>EPS Expectation: loss of $0.23</li>\n</ul>\n<p>Shares of <a href=\"https://laohu8.com/S/BYND\">Beyond Meat, Inc.</a> have remained under pressure throughout the pandemic as the veggie burger-maker struggled to increase its sales when restaurants, stadiums and campuses were closed.</p>\n<p><img src=\"https://static.tigerbbs.com/cb1491a08c273cf4bbed2a97d7f1c340\" tg-width=\"782\" tg-height=\"664\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">BYND Daily</p>\n<p>As the economy reopens and some of these avenues start again, investors are not convinced that sales will come back quickly. BYND shares have fallen 19% during the past month, illustrating investors' nervousness about owning this high-growth stock.</p>\n<p>When the Los Angeles-based company releases its second-quarter earnings tomorrow, one of the most important numbers to analyze is how quickly sales from restaurant and food-service sectors are rebounding.</p>\n<p>Unlike other packaged-food companies, Beyond Meat relies heavily on these segments for growth. The emergence of the Delta variant of COVID-19, which forced many countries to re-impose lockdowns and prompted US health authorities to reinstate mask mandates at indoor settings, is making the revenue outlook more uncertain for BYND.</p>\n<p>Despite the pandemic setback, we continue to believe Beyond Meat is a great food stock to own as consumers become more health conscious. Its recent weakness is a bump in the company’s long-term growth potential. BYND’s latest partnerships and expansion plans validate this bullish case.</p>\n<h2><b>A Clear Lead</b></h2>\n<p>A few years ago the big question was whether fake meat would take off. Now that it’s moving into the mainstream, the global market is projected to reach $450 billion by 2040,&nbsp;accordingto global consulting firm Kearney.</p>\n<p>And when it comes to competition, Beyond Meat is much further along than its closest rival, Impossible Foods. It had more US retailers—28,000 compared with Impossible’s 20,000. Its products were being offered in more restaurants (42,000 in the US vs. 30,000+), and more international markets (more than 80 vs. 5), according to a&nbsp;Bloomberg analysisin April.</p>\n<p>Beyond Meat this year announced several expansion plans that should ease investor anxiety, including a new burger, European retail expansion, and the opening of its production plant in China—its first outside the US—to produce and distribute its plant-based products, including Beyond Pork, created specifically for the Chinese market.</p>\n<p>In January, Beyond Meat finalized its agreements with <a href=\"https://laohu8.com/S/MCD\">McDonald's</a> and <a href=\"https://laohu8.com/S/YUM\">Yum</a>—two of the largest fast-food companies in the world. The three-year deal with McDonald’s makes Beyond Meat the chain’s “preferred supplier” for the McPlant patty. Beyond Meat and McDonald’s will also explore developing other plant-based menu items, including alternative chicken, pork and eggs.</p>\n<h3><b>Bottom Line</b></h3>\n<p>Beyond Meat sales will rebound quickly once the global economy overcomes the pandemic and people resume their routine activities. The company’s leading position in the plant-based food market makes it an ideal candidate to buy on weakness.</p>","source":"lsy1594375853987","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyond Meat Q2 Earnings: Restaurant Sales In Focus As Economy Reopens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-04 15:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860><strong>investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS Expectation: loss of $0.23\n\nShares of Beyond Meat, Inc. have remained under pressure throughout the...</p>\n\n<a href=\"https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BYND":"Beyond Meat, Inc."},"source_url":"https://www.investing.com/analysis/beyond-meat-q2-earnings-restaurant-sales-in-focus-as-economy-reopening-200595860","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174986187","content_text":"Reports Q2 results on Thursday, Aug. 5, after the market close\nRevenue Expectation: $143 billion\nEPS Expectation: loss of $0.23\n\nShares of Beyond Meat, Inc. have remained under pressure throughout the pandemic as the veggie burger-maker struggled to increase its sales when restaurants, stadiums and campuses were closed.\nBYND Daily\nAs the economy reopens and some of these avenues start again, investors are not convinced that sales will come back quickly. BYND shares have fallen 19% during the past month, illustrating investors' nervousness about owning this high-growth stock.\nWhen the Los Angeles-based company releases its second-quarter earnings tomorrow, one of the most important numbers to analyze is how quickly sales from restaurant and food-service sectors are rebounding.\nUnlike other packaged-food companies, Beyond Meat relies heavily on these segments for growth. The emergence of the Delta variant of COVID-19, which forced many countries to re-impose lockdowns and prompted US health authorities to reinstate mask mandates at indoor settings, is making the revenue outlook more uncertain for BYND.\nDespite the pandemic setback, we continue to believe Beyond Meat is a great food stock to own as consumers become more health conscious. Its recent weakness is a bump in the company’s long-term growth potential. BYND’s latest partnerships and expansion plans validate this bullish case.\nA Clear Lead\nA few years ago the big question was whether fake meat would take off. Now that it’s moving into the mainstream, the global market is projected to reach $450 billion by 2040, accordingto global consulting firm Kearney.\nAnd when it comes to competition, Beyond Meat is much further along than its closest rival, Impossible Foods. It had more US retailers—28,000 compared with Impossible’s 20,000. Its products were being offered in more restaurants (42,000 in the US vs. 30,000+), and more international markets (more than 80 vs. 5), according to a Bloomberg analysisin April.\nBeyond Meat this year announced several expansion plans that should ease investor anxiety, including a new burger, European retail expansion, and the opening of its production plant in China—its first outside the US—to produce and distribute its plant-based products, including Beyond Pork, created specifically for the Chinese market.\nIn January, Beyond Meat finalized its agreements with McDonald's and Yum—two of the largest fast-food companies in the world. The three-year deal with McDonald’s makes Beyond Meat the chain’s “preferred supplier” for the McPlant patty. Beyond Meat and McDonald’s will also explore developing other plant-based menu items, including alternative chicken, pork and eggs.\nBottom Line\nBeyond Meat sales will rebound quickly once the global economy overcomes the pandemic and people resume their routine activities. The company’s leading position in the plant-based food market makes it an ideal candidate to buy on weakness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}